Beihai Gofar Marine Biological Industry Co Ltd - Asset Resilience Ratio
Beihai Gofar Marine Biological Industry Co Ltd (600538) has an Asset Resilience Ratio of 0.13% as of June 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Beihai Gofar Marine Biological Industry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2020)
This chart shows how Beihai Gofar Marine Biological Industry Co Ltd's Asset Resilience Ratio has changed over time. See what is Beihai Gofar Marine Biological Industry 's book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Beihai Gofar Marine Biological Industry Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Beihai Gofar Marine Biological Industry (600538) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.29 Million | 0.13% |
| Total Liquid Assets | CN¥1.29 Million | 0.13% |
Asset Resilience Insights
- Limited Liquidity: Beihai Gofar Marine Biological Industry Co Ltd maintains only 0.13% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Beihai Gofar Marine Biological Industry Co Ltd Industry Peers by Asset Resilience Ratio
Compare Beihai Gofar Marine Biological Industry Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Yangnong Chemical Co Ltd
SHG:600486 |
Agricultural Inputs | 3.65% |
|
Chengdu Wintrue Holding Co Ltd
SHE:002539 |
Agricultural Inputs | 0.11% |
|
Hubei Yihua Chemical Industry Co Ltd
SHE:000422 |
Agricultural Inputs | 0.16% |
|
Shaanxi Meibang Pharmaceutical Group Co Ltd
SHG:605033 |
Agricultural Inputs | 18.19% |
|
Fanli Digital Technology Co Ltd
SHG:600228 |
Agricultural Inputs | 0.32% |
|
Insumos Agroquimicos SA
BA:INAG |
Agricultural Inputs | 1.46% |
|
Cho Bi
KO:001550 |
Agricultural Inputs | 0.00% |
|
Amoeba SA
PA:ALMIB |
Agricultural Inputs | 0.13% |
Annual Asset Resilience Ratio for Beihai Gofar Marine Biological Industry Co Ltd (2002–2020)
The table below shows the annual Asset Resilience Ratio data for Beihai Gofar Marine Biological Industry Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-12-31 | 1.52% | CN¥16.15 Million ≈ $2.36 Million |
CN¥1.07 Billion ≈ $155.95 Million |
-22.06pp |
| 2018-12-31 | 23.58% | CN¥180.00 Million ≈ $26.34 Million |
CN¥763.38 Million ≈ $111.71 Million |
+0.15pp |
| 2017-12-31 | 23.43% | CN¥182.00 Million ≈ $26.63 Million |
CN¥776.75 Million ≈ $113.66 Million |
+2.55pp |
| 2016-12-31 | 20.88% | CN¥200.00 Million ≈ $29.27 Million |
CN¥957.71 Million ≈ $140.14 Million |
+4.62pp |
| 2015-12-31 | 16.26% | CN¥160.00 Million ≈ $23.41 Million |
CN¥984.02 Million ≈ $143.99 Million |
+16.18pp |
| 2006-12-31 | 0.08% | CN¥1.00 Million ≈ $146.33K |
CN¥1.30 Billion ≈ $190.39 Million |
+0.06pp |
| 2005-12-31 | 0.02% | CN¥250.02K ≈ $36.59K |
CN¥1.27 Billion ≈ $185.50 Million |
-0.05pp |
| 2003-12-31 | 0.07% | CN¥492.57K ≈ $72.08K |
CN¥740.21 Million ≈ $108.32 Million |
-0.11pp |
| 2002-12-31 | 0.18% | CN¥421.53K ≈ $61.68K |
CN¥235.22 Million ≈ $34.42 Million |
-- |
About Beihai Gofar Marine Biological Industry Co Ltd
Beihai Gofar Chuanshan Biological Co., Ltd., together with its subsidiaries, engages in the distribution of pharmaceutical products in China. It operates through Pharmaceutical Distribution [Industry]; Pharmaceutical Manufacturing; DNA Testing Equipment, Consumables and Testing Services; and Others segments. The company wholesales and retails various medicines and medical devices through directly… Read more